Trioar
PrivateLast Round
Series B
Aug 28, 2025
Total Funding Raised
$31M
Company Overview
Trioar is a South Korean biotechnology company founded in 2021 that develops next-generation antibody-based therapeutics for cancer treatment. The company focuses on Antibody-Drug Conjugates (ADC) and Immuno-oncology (IO) and has developed proprietary platform technologies, TROCAD™ and TROSIG™, designed to improve the therapeutic index of treatments by reducing toxicity and enhancing efficacy. Trioar's pipeline includes programs such as anti-CLDN18.2 ADC and anti-EGFR ADC, which are currently in the pre-clinical phase. The company was founded by scientists with extensive experience in the field and has secured multiple rounds of funding to advance its research and development.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Trioar Comps
Public and private peers based on sector, stage, and business model.
Trioar Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 28, 2025 | ||||
| Series A | May 23, 2023 | ||||
| Pre Seed | Feb 24, 2022 |
Trioar Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Shinhan Venture Investment | Series B |
| KB Investment | Pre Seed, Series B, Series A |
| Kiwoom Investment | Series B, Series A |
| Hyundai Technology Investment | Series B |
| Jin & Investment Partners | Series B |
| LSK Investment | Series B, Series A |
| Regent Partners | Series B |
Trioar Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Trioar's valuation, stock price, and market status.
